Navigation Links
Investigational Study Demonstrated a Re-Establishment of Clinical,Improvement with Orencia (Abatacept) in Children with Juvenile,Idiopathic Arthritis upon Re-Introduction of Therapy

throat, and nausea.

For Full Prescribing Information, please visit www.ORENCIA.com or www.bms.com

Dosing and Administration

ORENCIA is administered by a healthcare professional as a 30-minute intravenous infusion at a fixed dose based on body weight range approximating 10 mg/kg at day 0, 2 weeks, 4 weeks, and every 4 weeks thereafter. Acute infusion-related reactions were experienced in nine percent of people treated with ORENCIA and in six percent of people treated with placebo. According to the full prescribing information, the most frequently reported infusion- related adverse events (1 percent to 2 percent) were dizziness, headache, and hypertension. In pivotal studies, premedications were not required. However, appropriate medical support measures for the treatment of hypersensitivity reactions should be available for immediate use in the event of a reaction.

About Juvenile Idiopathic Arthritis

ORENCIA is not FDA-approved for use in children with juvenile idiopathic arthritis (JIA).

JIA - also commonly known as juvenile rheumatoid arthritis (JRA) - is a chronic, autoimmune disease, causing chronic pain, stiffness and swelling of the joints, which may ultimately lead to joint damage and deformities. The disease usually begins before the age of 16 and may affect up to 1 child in every 1,000 in the United States. Despite current therapies, some individuals with JIA experience ongoing disease and many eventually worsen, resulting in severe joint damage and abnormal joint function.

About ORENCIA(R) (abatacept)

ORENCIA is indicated in the United States for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
5. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
6. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
11. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
Post Your Comments:
(Date:8/29/2014)... August 29, 2014 According ... Market by Extraction type (SFE, Cold Pressed, Organic ... Care, Pharmaceutical, Food Supplements, Fragrance, & Others) - Global ... defines and segments the Amaranth Seed Oil Market ... size in terms of value. The Amaranth Seed ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... Research and Development Trend Forecast of Pharmaceutical Equipment ... analyzes China,s pharmaceutical equipment industry ... demand, competition landscape, and business performance of domestic major ...
(Date:8/29/2014)... Corporation , a neurodiagnostics medical device company based in ... Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, FRCSEd  was ... " Teo Forcht Dagi is an experienced leader with ... said Remis Bistras , President and CEO of Vittamed. ... entrepreneurial expertise to our Board." Dr. Dagi is ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2
...  In a move aimed at bolstering current systems for assessing ... created a new method that combines multiple forms of widely ... which rely on detecting evidence of drug safety issues as ... may be able to identify issues years in advance. ...
... Systems, Inc. (NASDAQ: DCTH ) appointed Gregory ... "As a widely respected hepatologist and 2011 ... Gores will contribute a wealth of clinical knowledge on ... Advisory Board," said Eamonn P. Hobbs, CEO & President ...
Cached Medicine Technology:Taking a Predictive Approach to Identifying Adverse Drug Reactions 2Taking a Predictive Approach to Identifying Adverse Drug Reactions 3Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board 2Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board 3Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board 4
(Date:8/30/2014)... York, New York (PRWEB) August 30, 2014 ... other incretin mimetic claims continue to move forward in ... statement issued by AstraZeneca PLC on July 31, 2014, ... been named in 409 product liability claims that allege ... Court documents indicate that many of these claims are ...
(Date:8/30/2014)... CO (PRWEB) August 30, 2014 In today’s ... increasingly difficult to get. Snoring and sleep apnea (a medical ... rob people and their bed partners of the rest they ... 45% of the population snores and 20 million people in ... 10% have been diagnosed and treated; and of those treated, ...
(Date:8/30/2014)... Dallas, Texas (PRWEB) August 30, 2014 ... Lab Oven Industry, 2009-2019 is a professional and ... Oven industry. The report firstly reviews the basic ... and manufacturing technology. The report then explores global ... their product specification, capacity, production value, and market ...
(Date:8/30/2014)... August 30, 2014 The federal ... lawsuits ( http://www.injurybeacon.com/transvaginal-mesh/ ) filed against Boston Scientific ... four cases selected for one of the proceeding’s ... August 18, 2014, U.S. District Judge Joseph R. ... disagrees with Boston Scientific’s contention that a consolidated ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 In today’s ... and increasingly difficult to get. Snoring and sleep apnea ... and breathing stops) robs people and their bed partners ... challenges. Up to 45% of the population snores and ... sleep apnea. Of these, only 10% have been diagnosed ...
Breaking Medicine News(10 mins):Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Lab Oven Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... Nov. 6 The following was released today,by ... recent report from the U.S. Department of Veterans ... substantiated waste,mismanagement and inaction to disclosures of fraud, ... Texas Veterans Health,Care System (CTVHCS)., Inaction to ...
... ) today reported results for the third quarter ended September,30, ... or $0.11 per,share, for the third quarter 2008 compared to ... the third quarter 2007. Cash and cash equivalents,totaled $6.1 million ... for the third quarter 2008 is due primarily to,a 26% ...
... vitality unclear, scientists say , , THURSDAY, Nov. 6 (HealthDay ... amounts of muscle-linked growth hormone in seniors to youthful ... therapy also gained muscle mass over the two-year trial, ... led to significant improvements in their strength or function. ...
... Conference Call Scheduled for Today - Thursday, November 6, 2008 at ... ... Calif., Nov. 6 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) reported ... 30, 2008, and provided an,update on its product development candidates. The ...
... MASI ), the inventor of Pulse CO-Oximetry(TM) and ... its,management is scheduled to present at the Lazard Capital ... York in New York, NY on,Wednesday, November 19, 2008, ... will be available on the Masimo website at, http://www.masimo.com ...
... RANCHO CORDOVA, Calif., Nov. 6 ThermoGenesis,Corp. (Nasdaq: ... that process and store adult stem cells, today reported ... for the quarter ended September 30, 2008, were $4.5 ... in the first quarter a,year ago. Disposable revenues were ...
Cached Medicine News:Health News:War Veterans With Traumatic Brain Injury Pay the Price of Waste at the VA, Says Dr. Robert Van Boven 2Health News:Pharmos Corporation Reports 2008 Third Quarter Results 2Health News:Pharmos Corporation Reports 2008 Third Quarter Results 3Health News:Pharmos Corporation Reports 2008 Third Quarter Results 4Health News:Pharmos Corporation Reports 2008 Third Quarter Results 5Health News:Drug Boosts Natural Growth Hormone in Seniors 2Health News:Drug Boosts Natural Growth Hormone in Seniors 3Health News:Drug Boosts Natural Growth Hormone in Seniors 4Health News:Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates 2Health News:Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates 3Health News:Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates 4Health News:Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates 5Health News:Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates 6Health News:Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates 7Health News:Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates 8Health News:Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates 9Health News:Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates 10Health News:Masimo to Present at Lazard Capital Markets 5th Annual Healthcare Conference 2Health News:ThermoGenesis Reports First Quarter 2009 Results 2Health News:ThermoGenesis Reports First Quarter 2009 Results 3Health News:ThermoGenesis Reports First Quarter 2009 Results 4Health News:ThermoGenesis Reports First Quarter 2009 Results 5Health News:ThermoGenesis Reports First Quarter 2009 Results 6Health News:ThermoGenesis Reports First Quarter 2009 Results 7Health News:ThermoGenesis Reports First Quarter 2009 Results 8
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: